Evidence map›Paper›PMID 27496614›Full record

ArticleJournal of inorganic biochemistry2016

Design and cellular studies of a carbon nanotube-based delivery system for a hybrid platinum-acridine anticancer agent.

Cale D Fahrenholtz, Song Ding, Brian W Bernish, Mariah L Wright, Ye Zheng, Mu Yang, Xiyuan Yao, George L Donati, Michael D Gross, Ulrich Bierbach and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of inorganic biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Acridine as an Anti-Tumour Agent: A Critical Review.Molecules (Basel, Switzerland) · 2022
    Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Cale D FahrenholtzDepartment of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Electronic address: cfahrenh@wakehealth.edu.
Song DingDepartment of Chemistry, Wake Forest University, Winston-Salem, NC 27109, USA. Electronic address: dings0@wfu.edu.
Brian W BernishDepartment of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Electronic address: bbernish@wakehealth.edu.
Mariah L WrightDepartment of Chemistry, Wake Forest University, Winston-Salem, NC 27109, USA. Electronic address: mariah.l.wright@alumni.wfu.edu.
Ye ZhengDepartment of Chemistry, Wake Forest University, Winston-Salem, NC 27109, USA. Electronic address: zheny9@wfu.edu.
Mu YangDepartment of Chemistry, Wake Forest University, Winston-Salem, NC 27109, USA. Electronic address: yangm11@wfu.edu.
Xiyuan YaoDepartment of Chemistry, Wake Forest University, Winston-Salem, NC 27109, USA. Electronic address: yaox15@wfu.edu.
George L DonatiDepartment of Chemistry, Wake Forest University, Winston-Salem, NC 27109, USA. Electronic address: donatigl@wfu.edu.
Michael D GrossDepartment of Chemistry, Wake Forest University, Winston-Salem, NC 27109, USA. Electronic address: grossmd@wfu.edu.
Ulrich BierbachDepartment of Chemistry, Wake Forest University, Winston-Salem, NC 27109, USA; Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA. Electronic address: bierbau@wfu.edu.
Ravi SinghDepartment of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA. Electronic address: rasingh@wakehealth.edu.
Wake Forest University · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
Training Program in Cancer BiologyT32CA079448 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KRIDEL, STEVEN J. · 2000 to 2014
$6.5M
Novel DNA-metalating Hybrid Anticancer AgentsR01CA101880 · NCI · WAKE FOREST UNIVERSITY · PI BIERBACH, ULRICH · 2003 to 2012
$1.8M
Development of a novel therapeutic agent that exploits specific vulnerabilities in claudin low breast cancerR01CA207222 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SINGH, RAVI N · 2017 to 2021
$1.7M
Tumor Targeting and Diagnostic Applications of Glycosylated NanotubesR00CA154006 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SINGH, RAVI N · 2012 to 2014
$697k
Tumor Targeting and Diagnostic Applications of Glycosylated NanotubesK99CA154006 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SINGH, RAVI N · 2010 to 2011
$257k
1st International Symposium on Clinical and Experimental Metallodrugs in Medicine: Cancer ChemotherapyR13CA200223 · NCI · BROOKLYN COLLEGE · PI CONTEL, MARIA · 2016 to 2016
$5k
NCI NIH HHS K99 CA154006NCI NIH HHS P30 CA012197NCI NIH HHS R00 CA154006NCI NIH HHS R01 CA101880NCI NIH HHS R01 CA207222NCI NIH HHS R13 CA200223NCI NIH HHS T32 CA079448
6 · The paper itself

Abstract

A three-component drug-delivery system has been developed consisting of multi-walled carbon nanotubes (MWCNTs) coated with a non-classical platinum chemotherapeutic agent ([PtCl(NH

Indexed as

AcridinesAntineoplastic AgentsPlatinumBreast NeoplasmsCell Line, TumorDrug Delivery SystemsFemaleHumansHyperthermia, InducedNanotubes, CarbonPhototherapyAcridinesAntineoplastic AgentsNanotubes, CarbonPlatinumChemotherapyCytotoxicityDrug deliveryNanoparticlePhotothermal therapyTriple negative breast cancer

Identifiers

PMID27496614
PMCPMC5154932
OpenAlexW2477864239

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.